Expertise in
1
conditions

Dr. Valerie Arnold

Child and Adolescent Psychiatry
Le Bonheur Children's Outpatient Center
51 N Dunlap St, 
Memphis, TN 
Offers Telehealth
Expertise in
1
conditions
Le Bonheur Children's Outpatient Center
51 N Dunlap St, 
Memphis, TN 

Overview

Valerie Arnold is a Child and Adolescent Psychiatrist in Memphis, Tennessee. Dr. Arnold is highly rated in 1 condition, according to our data. Her top areas of expertise are Attention Deficit Hyperactivity Disorder (ADHD) and Major Depression.

Her clinical research consists of co-authoring 13 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Child and Adolescent Psychiatry

Licenses

Child & Adolescent Psychiatry in TN

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 2 Less Insurance Carriers -

Locations

Le Bonheur Children's Outpatient Center
51 N Dunlap St, Memphis, TN 38105

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Phase 4, Multicenter, 2-part Study Composed of a Randomized, Double-blind, Parallel-group, Placebo-controlled, Active-comparator, Dose-optimization Evaluation Followed by a 1-Year Open-label Evaluation to Assess the Safety and Efficacy of Guanfacine Hydrochloride Prolonged-release (SPD503) in Children and Adolescents Aged 6 to 17 Years With Attention-deficit/Hyperactivity Disorder
A Phase 4, Multicenter, 2-part Study Composed of a Randomized, Double-blind, Parallel-group, Placebo-controlled, Active-comparator, Dose-optimization Evaluation Followed by a 1-Year Open-label Evaluation to Assess the Safety and Efficacy of Guanfacine Hydrochloride Prolonged-release (SPD503) in Children and Adolescents Aged 6 to 17 Years With Attention-deficit/Hyperactivity Disorder
Enrollment Status: Completed
Publish Date: September 08, 2025
Intervention Type: Drug, Other
Study Drugs: Guanfacine hydrochloride (TAK-503), Atomoxetine hydrochloride
Study Phase: Phase 4
A Phase 2a, Randomized, Double-blind, Placebo-controlled Proof of Concept Study to Evaluate the Effects of Oral BTRX-335140 (NMRA-335140) Versus Placebo in Subjects With Major Depressive Disorder
A Phase 2a, Randomized, Double-blind, Placebo-controlled Proof of Concept Study to Evaluate the Effects of Oral BTRX-335140 (NMRA-335140) Versus Placebo in Subjects With Major Depressive Disorder
Enrollment Status: Completed
Publish Date: May 29, 2025
Intervention Type: Drug
Study Drug: BTRX-335140
Study Phase: Phase 2
An Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule) in Adults With Attention-Deficit/Hyperactivity Disorder
An Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule) in Adults With Attention-Deficit/Hyperactivity Disorder
Enrollment Status: Completed
Publish Date: February 13, 2024
Intervention Type: Drug
Study Drug: SPN-812
Study Phase: Phase 3
A Multicenter, Dose-Optimized, Open-Label Safety Study With KP415 in Children With Attention-Deficit/Hyperactivity Disorder
A Multicenter, Dose-Optimized, Open-Label Safety Study With KP415 in Children With Attention-Deficit/Hyperactivity Disorder
Enrollment Status: Completed
Publish Date: July 19, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Phase 3, Randomized, Double-blind, Multicenter, Parallel-group, Placebo-controlled, Fixed-Dose Safety and Efficacy Study of SPD489 Compared With Placebo in Preschool Children Aged 4-5 Years With Attention-deficit/Hyperactivity Disorder
A Phase 3, Randomized, Double-blind, Multicenter, Parallel-group, Placebo-controlled, Fixed-Dose Safety and Efficacy Study of SPD489 Compared With Placebo in Preschool Children Aged 4-5 Years With Attention-deficit/Hyperactivity Disorder
Enrollment Status: Completed
Publish Date: June 08, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Phase 3, Open-label, Multicenter, 12-Month Safety and Tolerability Study of SHP465 in Children Aged 4 to 12 Years Diagnosed With Attention-deficit/Hyperactivity Disorder
A Phase 3, Open-label, Multicenter, 12-Month Safety and Tolerability Study of SHP465 in Children Aged 4 to 12 Years Diagnosed With Attention-deficit/Hyperactivity Disorder
Enrollment Status: Terminated
Publish Date: June 03, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Phase 3, Open-label, Multicenter, 12-Month Safety and Tolerability Study of SPD489 in Preschool Children Aged 4-5 Years Diagnosed With Attention-deficit / Hyperactivity Disorder
A Phase 3, Open-label, Multicenter, 12-Month Safety and Tolerability Study of SPD489 in Preschool Children Aged 4-5 Years Diagnosed With Attention-deficit / Hyperactivity Disorder
Enrollment Status: Completed
Publish Date: March 05, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Double-Blind Placebo-Controlled Phase II Study to Determine the Efficacy, Safety, Tolerability and Pharmacokinetics of a Controlled Release (CR) Formulation of Mazindol in Adults With DSM-5 Attention Deficit Hyperactivity Disorder (ADHD)
A Double-Blind Placebo-Controlled Phase II Study to Determine the Efficacy, Safety, Tolerability and Pharmacokinetics of a Controlled Release (CR) Formulation of Mazindol in Adults With DSM-5 Attention Deficit Hyperactivity Disorder (ADHD)
Enrollment Status: Completed
Publish Date: April 06, 2017
Intervention Type: Drug
Study Phase: Phase 2
A Phase 2, Double-Blind, Placebo-Controlled Study of NSI-189, a Neurogenic Compound Among Out-Patients With Major Depressive Disorder
A Phase 2, Double-Blind, Placebo-Controlled Study of NSI-189, a Neurogenic Compound Among Out-Patients With Major Depressive Disorder
Enrollment Status: Unknown
Publish Date: February 24, 2017
Intervention Type: Drug
Study Drug: NSI-189
Study Phase: Phase 2
View 8 Less Clinical Trials

13 Total Publications

A Phase 2, multicenter, double-blind, randomized, placebo-controlled study of the safety and efficacy of forvisirvat (SP-624) in the treatment of adults with major depressive disorder.
A Phase 2, multicenter, double-blind, randomized, placebo-controlled study of the safety and efficacy of forvisirvat (SP-624) in the treatment of adults with major depressive disorder.
Journal: Current medical research and opinion
Published: October 16, 2025
Similar Doctors
Expertise in
4
conditions
Dr. Nga Huynh
Child and Adolescent Psychiatry
Expertise in
4
conditions
Dr. Nga Huynh
Child and Adolescent Psychiatry

Roger Vogelfanger

6005 Park Ave Ste 630B, 
Memphis, TN 
 (8.7 miles away)
901-767-1136
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Nga Huynh is a Child and Adolescent Psychiatrist in Memphis, Tennessee. Dr. Huynh is highly rated in 4 conditions, according to our data. Her top areas of expertise are Generalized Anxiety Disorder (GAD), Seasonal Affective Disorder (SAD), Major Depression, and Bipolar Disorder (BPD).

Expertise in
2
conditions
Dr. Otis A. Iii
Child and Adolescent Psychiatry
Expertise in
2
conditions
Dr. Otis A. Iii
Child and Adolescent Psychiatry

First Pharmacy Compounding Services

5185 Getwell Rd, 
Southaven, MS 
 (10.0 miles away)
662-349-6385
Languages Spoken:
English

Otis Iii is a Child and Adolescent Psychiatrist in Southaven, Mississippi. Dr. Iii is highly rated in 2 conditions, according to our data. His top areas of expertise are Dementia, Bipolar Disorder (BPD), Major Depression, and Seasonal Affective Disorder (SAD).

Expertise in
6
conditions
Dr. David Struble
Child and Adolescent Psychiatry
Expertise in
6
conditions
Dr. David Struble
Child and Adolescent Psychiatry

Roger Vogelfanger

6005 Park Ave Ste 630B, 
Memphis, TN 
 (8.7 miles away)
901-767-1136
Languages Spoken:
English
See accepted insurances
Offers Telehealth

David Struble is a Child and Adolescent Psychiatrist in Memphis, Tennessee. Dr. Struble is highly rated in 6 conditions, according to our data. His top areas of expertise are Seasonal Affective Disorder (SAD), Major Depression, Generalized Anxiety Disorder (GAD), and Bipolar Disorder (BPD).

Frequently Asked Questions about Dr. Valerie Arnold

How do I make an appointment with Dr. Valerie Arnold?

You can book an appointment with Dr. Valerie Arnold by calling their office at 866-870-5570. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Valerie Arnold a top-rated expert for Attention Deficit Hyperactivity Disorder (ADHD)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Valerie Arnold is classified as an Distinguished expert for Attention Deficit Hyperactivity Disorder (ADHD), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Valerie Arnold specialize in?

While Dr. Valerie Arnold is a Child and Adolescent Psychiatry, they have specific expertise in Attention Deficit Hyperactivity Disorder (ADHD), Major Depression. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Child and Adolescent Psychiatry.

Does Dr. Valerie Arnold participate in research or clinical trials?

Yes. Dr. Valerie Arnold has published 13 articles and abstracts on conditions like Attention Deficit Hyperactivity Disorder (ADHD). You can view a list of Dr. Valerie Arnold's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Valerie Arnold accept my insurance?

Dr. Valerie Arnold accepts most major insurance plans, including Blue Cross Blue Shield and Cigna. We recommend calling the office directly at 866-870-5570 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Arnold's expertise for a condition
ConditionClose
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile